SCHEMBL2169554

SCHEMBL2169554

CC1(C)C(=O)N(C2[C@@H]3CC4C[C@H]2CC(O)(C4)C3)N1Cc1ccccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 10/20 0.41
P2RX7 Q99572 1/20 0.39
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
IDH1 O75874 1/20 0.36
MAPK8 P45983 1/20 0.35
RAB9A P51151 1/20 0.35
REN P00797 1/20 0.35
HSD11B2 P80365 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2169528 1.00 HSD11B1 (0.41) HSD11B1P2RX7MEN1KMT2ANPSR1
SCHEMBL12012544 1.00 HSD11B1 (0.41) HSD11B1P2RX7MEN1KMT2ANPSR1
SCHEMBL2170377 1.00 HSD11B1 (0.41) HSD11B1P2RX7MEN1KMT2ANPSR1
SCHEMBL2168311 0.87 HSD11B1 (0.42) HSD11B1P2RX7MEN1KMT2ANPSR1
SCHEMBL2168703 0.87 P2RX7 (0.40) HSD11B1P2RX7MEN1KMT2ANPSR1
SCHEMBL2181247 0.86 HSD11B1 (0.40) HSD11B1P2RX7ALDH1A1SMN1; SMN2REN
SCHEMBL2181244 0.86 HSD11B1 (0.40) HSD11B1P2RX7ALDH1A1SMN1; SMN2REN
SCHEMBL12012546 0.86 HSD11B1 (0.40) HSD11B1P2RX7ALDH1A1SMN1; SMN2REN
SCHEMBL2169762 0.86 HSD11B1 (0.44) HSD11B1RENHSD11B2
SCHEMBL12012545 0.85 HSD11B1 (0.39) HSD11B1P2RX7MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US claimed
EP-2348019-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2011-07-27 EP claimed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US claimed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
EP-2348019-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2011-07-27 EP disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 HSD11B1 1/4885P2RX7 4755/4885MEN1 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.